Caribou Biosciences, Inc. (CRBU) · Nov 5, 2026 · Earnings
In line — Net loss $26.6M vs $27.5M prior year; no new operating plan
Caribou’s earnings show a slightly smaller quarterly loss and lower expenses, but the October decision to halt its CAR-T pipeline still defines the business.
Caribou is no longer operating as a normal clinical-stage biotech: after previously funding vispa-cel and CB-011 toward pivotal development, it announced on October 6, 2026 that it would stop both programs, cut its workforce, and pursue strategic alternatives. Its prior second-quarter plan had contemplated funding selected development work through the end of 2027, but that operating strategy was overtaken by the restructuring announcement.
The quarter’s financial update is mostly housekeeping after the strategic reset. Revenue fell to $1.6 million from $2.2 million a year earlier, while the net loss narrowed only modestly to $26.6 million from $27.5 million.
| Q3 2026 | Q3 2025 | Year-end 2025 | |
|---|---|---|---|
| Licensing revenue (Financial Highlights) | $1.6M (-26.9%) | $2.2M | |
| Net loss (Financial Highlights) | $26.6M (-3.4%) | $27.5M | |
| Diluted loss per share (Financial Highlights) | $0.25 | $0.30 | |
| Cash and marketable securities (Balance Sheet) | $94.8M | $142.8M |
Cost control is visible, but it does not revive the operating story. Research and development and general and administrative spending both declined year over year, consistent with the workforce reduction and pipeline shutdown. That helped narrow the loss, but cash and marketable securities fell to $94.8 million from $142.8 million at December 31, 2025.
The genuinely important news was already public. The filing repeats that Caribou is discontinuing further development of vispa-cel and CB-011 while exploring a merger, acquisition, business combination, asset transaction, or possible liquidation. 〔0〕 The company provides no timetable or new transaction detail, so this earnings release does not materially change the post-shutdown situation.
Bottom line: The numbers show modest expense discipline but continued cash depletion and shrinking revenue. Because the pipeline halt and strategic review were already disclosed, this filing is routine confirmation rather than a new change to Caribou’s business story.
Strategic alternatives review outcome
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!